ClinicalTrials.gg
CompletedNCT04213807Updated Jan 11, 2022Results posted

A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation

A Phase 2 interventional study of MAA868 Cohort 1 and MAA868 Cohort 2 in Atrial Fibrillation, sponsored by Anthos Therapeutics, Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-01-11.

Sponsored by Anthos Therapeutics, Inc. · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 993 studies in Atrial Fibrillation with a site in United States — 161 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.

Enrollment
541st of 679
28 · median 127
Started
2019
with 57 others
Phase 2
55 of 993
7 open now
Registered
642nd of 993
by date

Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 541st largest by enrollment of the 679 interventional ones that give a count, is one of 58 that started in 2019, is one of 55 in phase 2, and was the 642nd registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

161 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:

156 more — sign in →

All 161 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 993 studies in Atrial Fibrillation with a site in United States, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, subject and Investigator-blinded, placebo-controlled, parallel-group, multiple ascending dose-ranging study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) effects of MAA868 in patients with atrial fibrillation (AF) or flutter at low risk of thromboembolic stroke or peripheral embolism.

03

Conditions studied

  • Atrial Fibrillation

Keywords

  • atrial fibrillation
  • flutter
  • paroxysmal atrial fibrillation
  • stroke
  • cardiac arrhythmia
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients ≥ 18 and \< 85 years old with paroxysmal atrial fibrillation (PAF) or atrial flutter on 12 lead electrocardiography at Screening Or
  • Patients with a history of PAF or atrial flutter, as documented by (telemetry, 12 lead electrocardiography or ambulatory [e.g. Holter] monitor) and not due to a reversible condition (e.g. alcohol binge drinking) can be entered even if they do not have PAF at Screening. There is not time-limit for this.
  • Patients with a Congestive heart failure, Hypertension, Age ( > 65 = 1 point, > 75 = 2 points), Diabetes, previous Stroke/ (2 points) (CHA2DS2-VASc) risk score (tool as a predictor for estimating the risk of stroke in patients with atrial fibrillation (AF); Lip et al 2010) of 0-1 for men and 1-2 for women and in whom, in the investigator's judgment, the use of an anticoagulant for stroke prevention is not indicated

Exclusion criteria

Exclusion Criteria:

  • History of stroke, or systemic embolism
  • History of major bleeding during treatment with an anticoagulant or antiplatelet therapy. (Patients who have had major bleeding on anticoagulants or antiplatelet therapy more than a year ago can be enrolled only if the bleeding was due to a reversible cause, e.g. gastro-duodenal ulcer that was successfully treated.)
  • History of traumatic or non-traumatic intracranial, intraspinal or intraocular bleeding
  • Known bleeding diathesis or any known active bleeding site at screening or baseline
  • Family history of bleeding disorder
  • Known active GI lesions predisposing to bleeding events
  • Myocardial infarction, unstable angina pectoris or coronary artery bypass graft (CABG) surgery within 12 months prior to the Screening period
  • Known valvular heart disease including moderate or severe mitral stenosis (valve area \<1.5 cm2)
  • Patients with a prosthetic heart valve

Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    MAA868

    Subcutaneous injection on Day 1 with two subsequent monthly injections

    Biological: MAA868 Cohort 1 · Biological: MAA868 Cohort 2 · Biological: MAA868 Cohort 3

  • Placebo comparator
    Placebo

    Subcutaneous injection: Placebo on Day 1 with two subsequent monthly injections

    Other: Placebo

Interventions

  • BiologicalMAA868 Cohort 1

    Subcutaneous injection: low dose

  • BiologicalMAA868 Cohort 2

    Subcutaneous injection: high dose

  • BiologicalMAA868 Cohort 3

    Subcutaneous injection: Dose to be determined.

  • OtherPlacebo

    Subcutaneous injection: Placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants That Achieved More Than or Equal to 50%, 80%, and 90% Factor XI Inhibition at Trough After the Third Dose (Day 91) at Different Dose Levels of MAA868

    Number of participants achieving more than or equal to 50%, 80%, and 90% inhibition of factor XI (less than 50%, 20%, or 10% free factor XI) at trough after the third dose on Day 91 at different dose levels of MAA868

    Time frame: Day 91

Secondary outcomes

  1. Number of Participants Achieving More Than or Equal to 50%, 80%, and 90% Factor XI Inhibition at Trough After First (Day 31) and Second Doses (Day 61) at Different Dose Levels of MAA868

    Number of participants achieving more than or equal to 50%, 80%, and 90% inhibition of factor XI (less than 50%, 20%, or 10% free factor XI) at trough on Day 31 (after first dose) and Day 61 (after second dose) at different dose levels of MAA868

    Time frame: Day 31 and Day 61

  2. Overall Number of Participants Who Experienced Adverse Events, Including Serious Adverse Events, During the Treatment Period and Through End of Study

    Overall number of participants who experienced adverse events following multiple subcutaneous administration of MAA868 compared to placebo in participants with atrial fibrillation or atrial flutter

    Time frame: Day 1 through end of study, up to 170 days

  3. Incidence of Major Bleeding Events, Clinically Relevant Non-major Bleeding Events and Total Bleeding With MAA868 Relative to Placebo

    Occurrence of confirmed major bleeding events, clinically relevant non-major bleeding events and total bleeding events during the treatment period

    Time frame: Day 1 through end of study, up to 170 days

  4. Immunogenicity of MAA868

    Number of participants with anti-drug (MAA868) antibodies for all participants who received MAA868 120 mg or MAA868 180 mg. "Non-evaluable observation" refers to participants who had no sample collected (due to no visit or remote visit) or for whom the sample was not frozen.

    Time frame: Days 1, 31, 61, 71, 91, 121 and 170

07

Results

Posted Dec 7, 2021

Participant flow

No subjects were enrolled in the optional Cohort 3.

Participant flow — Overall Study
MilestonePlaceboMAA868 120 mgMAA868 180 mg
Started567
Completed566
Not completed001
Withdrew: Physician decision001

Outcome measures

PrimaryNumber of Participants That Achieved More Than or Equal to 50%, 80%, and 90% Factor XI Inhibition at Trough After the Third Dose (Day 91) at Different Dose Levels of MAA868

Number of participants achieving more than or equal to 50%, 80%, and 90% inhibition of factor XI (less than 50%, 20%, or 10% free factor XI) at trough after the third dose on Day 91 at different dose levels of MAA868

Time frame:
Day 91
Reported as:
Count of participants · Participants
Number of Participants That Achieved More Than or Equal to 50%, 80%, and 90% Factor XI Inhibition at Trough After the Third Dose (Day 91) at Different Dose Levels of MAA868
ParticipantsPlaceboMAA868 120 mgMAA868 180 mg
More than or equal to 50% inhibition of factor XI024
More than or equal to 80% inhibition of factor XI001
More than or equal to 90% inhibition of factor XI000
SecondaryNumber of Participants Achieving More Than or Equal to 50%, 80%, and 90% Factor XI Inhibition at Trough After First (Day 31) and Second Doses (Day 61) at Different Dose Levels of MAA868

Number of participants achieving more than or equal to 50%, 80%, and 90% inhibition of factor XI (less than 50%, 20%, or 10% free factor XI) at trough on Day 31 (after first dose) and Day 61 (after second dose) at different dose levels of MAA868

Time frame:
Day 31 and Day 61
Reported as:
Count of participants · Participants
Number of Participants Achieving More Than or Equal to 50%, 80%, and 90% Factor XI Inhibition at Trough After First (Day 31) and Second Doses (Day 61) at Different Dose Levels of MAA868
ParticipantsPlaceboMAA868 120 mgMAA868 180 mg
More than or equal to 50% factor XI inhibition : Day 31015
More than or equal to 50% factor XI inhibition : Day 61025
More than or equal to 80% factor XI inhibition : Day 31013
More than or equal to 80% factor XI inhibition : Day 61001
More than or equal to 90% factor XI inhibition : Day 31000
More than or equal to 90% factor XI inhibition : Day 61000
SecondaryOverall Number of Participants Who Experienced Adverse Events, Including Serious Adverse Events, During the Treatment Period and Through End of Study

Overall number of participants who experienced adverse events following multiple subcutaneous administration of MAA868 compared to placebo in participants with atrial fibrillation or atrial flutter

Time frame:
Day 1 through end of study, up to 170 days
Reported as:
Count of participants · Participants
Overall Number of Participants Who Experienced Adverse Events, Including Serious Adverse Events, During the Treatment Period and Through End of Study
ParticipantsPlaceboMAA868 120 mgMAA868 180 mg
Overall Number of Participants Who Experienced Adverse Events, Including Serious Adverse Events, During the Treatment Period and Through End of Study453
SecondaryIncidence of Major Bleeding Events, Clinically Relevant Non-major Bleeding Events and Total Bleeding With MAA868 Relative to Placebo

Occurrence of confirmed major bleeding events, clinically relevant non-major bleeding events and total bleeding events during the treatment period

Time frame:
Day 1 through end of study, up to 170 days
Reported as:
Number · incidence of events
Incidence of Major Bleeding Events, Clinically Relevant Non-major Bleeding Events and Total Bleeding With MAA868 Relative to Placebo
incidence of eventsPlaceboMAA868 120 mgMAA868 180 mg
Major bleeding events000
Clinically relevant non-major bleeding events000
Nuisance (not clinically relevant) bleeding events211
No bleeding events010
SecondaryImmunogenicity of MAA868

Number of participants with anti-drug (MAA868) antibodies for all participants who received MAA868 120 mg or MAA868 180 mg. "Non-evaluable observation" refers to participants who had no sample collected (due to no visit or remote visit) or for whom the sample was not frozen.

Time frame:
Days 1, 31, 61, 71, 91, 121 and 170
Reported as:
Count of participants · Participants
Immunogenicity of MAA868
ParticipantsMAA868 120 mgMAA868 180 mg
Baseline — Negative67
Baseline — Positive00
Baseline — Non-evaluable observation00
Day 1 — Negative67
Day 1 — Positive00
Day 1 — Non-evaluable observation00
Day 31 — Negative67
Day 31 — Positive00
Day 31 — Non-evaluable observation00
Day 61 — Negative36
Day 61 — Positive00
Day 61 — Non-evaluable observation31
Day 71 — Negative46
Day 71 — Positive00
Day 71 — Non-evaluable observation21
Day 91 — Negative55
Day 91 — Positive00
Day 91 — Non-evaluable observation12
Day 121 — Negative55
Day 121 — Positive00
Day 121 — Non-evaluable observation12
Day 170 — Negative67
Day 170 — Positive00
Day 170 — Non-evaluable observation00

Adverse events

Collected over Adverse event information was collected at every study visit from providing written informed consent for participation in the study (on Days -28 to -3) until Day 170 (the end of study visit).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/5 (0%)0/5 (0%)4/5 (80%)
MAA868 120 mg0/6 (0%)0/6 (0%)5/6 (83.3%)
MAA868 180 mg0/7 (0%)0/7 (0%)3/7 (42.9%)
Most frequent other events
Showing 10 of 28
Most frequent other events
EventPlaceboMAA868 120 mgMAA868 180 mg
Back painMusculoskeletal and connective tissue disorders1/50/61/7
Muscle spasmsMusculoskeletal and connective tissue disorders1/50/60/7
DiarrhoeaGastrointestinal disorders1/51/60/7
Blood pressure increasedInvestigations1/50/60/7
Eosinophil count increasedInvestigations1/50/60/7
Renal impairmentRenal and urinary disorders1/50/60/7
ContusionInjury, poisoning and procedural complications1/50/60/7
HaematomaVascular disorders1/50/60/7
ArthralgiaMusculoskeletal and connective tissue disorders0/51/60/7
Pain in extremityMusculoskeletal and connective tissue disorders0/51/60/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboMAA868 120 mgMAA868 180 mgTotal
Mean52.2 ± 18.7953.8 ± 9.2458.1 ± 8.3455.1 ± 11.81
Age, Customized
Age, Customized(years)PlaceboMAA868 120 mgMAA868 180 mgTotal
18 to 201001
21 to 300000
31 to 400101
41 to 500011
51 to 6024410
61 to 702125
71 to 800000
81 to 850000
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMAA868 120 mgMAA868 180 mgTotal
Female0325
Male53513
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboMAA868 120 mgMAA868 180 mgTotal
Hispanic or Latino0000
Not Hispanic or Latino56718
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboMAA868 120 mgMAA868 180 mgTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0022
White56516
More than one race0000
Unknown or Not Reported0000
Height
Height(centimeters)PlaceboMAA868 120 mgMAA868 180 mgTotal
Mean182.01 ± 5.573174.60 ± 11.311175.74 ± 8.337177.10 ± 8.918
Weight
Weight(kg)PlaceboMAA868 120 mgMAA868 180 mgTotal
Mean99.352 ± 13.171591.667 ± 7.110294.933 ± 23.274595.072 ± 16.0115
Body mass index
Body mass index(kg/m^2)PlaceboMAA868 120 mgMAA868 180 mgTotal
Mean30.022 ± 4.164730.392 ± 4.755830.887 ± 8.675430.482 ± 6.1179
08

Study locations

6 sites
  • Anthos Investigative Site
    Beverly Hills, California 90211, United States
  • Anthos Investigative Site
    Wichita, Kansas 67207, United States
  • Anthos Investigative Site
    Alexandria, Louisiana 71301, United States
  • Anthos Investigative Site
    Lansing, Michigan 48912, United States
  • Anthos Investigative Site
    Wynnewood, Pennsylvania 19096, United States
  • Anthos Investigative Site
    McKinney, Texas 75069, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Dec 2020, 12 months.

Results were first posted in Dec 2021, 11 months after primary completion.

Of 41 phase 2 interventional studies under Atrial Fibrillation, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2019
First posted
Dec 30, 2019
StartActual
Dec 11, 2019
Primary completionActual
Dec 29, 2020
CompletionActual
Mar 8, 2021
Results first posted
Dec 7, 2021
Last update
Jan 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04213807
Lead sponsor
Anthos Therapeutics, Inc.
Collaborators
Covance
Responsible party
Sponsor
First posted
Dec 30, 2019
Start date
Dec 11, 2019
Primary completion
Dec 29, 2020
Completion
Mar 8, 2021
Results posted
Dec 7, 2021
Last update
Jan 11, 2022

Study contacts

Norman E Lepor, MD FACC FAHA FSCAI
principal investigator · Westside Medical Associates of Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abelacimab

Start the discussion